Research

Biomolecules from yeast for innovative drugs: the Arzanya spinoff

The recent health emergency has emphasised the need for the development of advanced technologies to quickly identify new-generation drugs that are safe, affordable, and have a reduced environmental impact. The Ca' Foscari spinoff Arzanya was established specifically to address the emerging needs of the healthcare system and pharmaceutical companies. It offers an innovative solution for identifying biomolecules and has the ability to translate biotechnological research into practical outcomes for human well-being.